Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.

Abstract

Recently, a new therapy involving an extracorporal activation of orally administered 8-methoxypsoralen (8-MOP), photosensitizing furocoumarin, is established for the treatment of different skin diseases, extracorporeal photopheresis (ECP). The pharmacokinetic profile of 8-MOP has been pursued as part of a clinical study which should assess the efficacy of ECP in patients with progressive systemic sclerosis and cutaneous T-cell lymphoma. The enormous intra-individual variations proofed for plasma as well as buffy coat concentration are unfavourable for oral 8-MOP therapy. Therefore, the introduction of liquid 8-MOP formulation that allows the direct administration of the drug in to the treatment bag of the ECP device is challenging.

• Authors: A Balogh, U Merkel, A Looks, R Vollandt, U Wollina
• Journal: Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie (Exp Toxicol Pathol) Vol. 50 Issue 4-6 Pg. 397-401 (Sep 1998) ISSN: 0940-2993 [Print] Germany
• PMID: 9784014 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Photosensitizing Agents
• Methoxsalen

Topics

• Adult
• Aged
• Aged, 80 and over
• Area Under Curve
• Female
• Humans
• Leukapheresis
• Lymphoma, T-Cell (blood, drug therapy)
• Male
• Methoxsalen (pharmacokinetics, therapeutic use)
• Middle Aged
• PUVA Therapy
• Photopheresis (methods)
• Photosensitizing Agents (pharmacokinetics, therapeutic use)
• Scleroderma, Systemic (blood, drug therapy)
• Skin Neoplasms (blood, drug therapy)